Taiwan has decided to request a "coercive authorization" to produce Tamiflu, as the drug's patent holder, Roche Holding AG, is still reluctant to give the nation permission to make the drug that can be used to treat bird flu in people.
Taiwan will send the formal notice to Roche, the second-largest Swiss drugmaker, as soon as next week, Jack Lu (盧文祥), deputy director general of the Intellectual Property Office (IPO), said after concluding a meeting on the issue yesterday evening.
The IPO yesterday invited representatives from the Department of Health, Roche Taiwan, the local office of US biotech firm Gilead that developed Tamiflu, as well as several academics in the fields of public hygiene, patents and international trade to discuss the issues and try to reach a conclusion about licensing.
The authorization, which is also known as a compulsory license, will be valid through the end of 2007, and is expected to help Taiwan prepare for any possible outbreak of avian influenza among humans.
But the authorization is being issued with several conditions, Lu said.
First, any drugs produced under the coercive authorization would be restricted for use in Taiwan, Lu said. In other words, Taiwan could not sell or export the drugs overseas.
Secondly, Taiwan can only start production of the anti-viral drugs when its stocks of Tamiflu and those that have been ordered from Roche are depleted, he added.
Currently, Taiwan has a stockpile of 130,000 doses of Tamiflu, and will receive another 80,000 by the end of January. Another 390,000 are due to be delivered in February, Lu said. In addition, Roche has consented to supply enough of the drug's raw materials to produce 2.3 million doses, enough for 10 percent of Taiwan's population, Lu said.
As Taiwan is still negotiating with Roche about gaining formal permission to produce Tamiflu, once Roche agrees to license Taiwan to make the drug, the coercive authorization will be recalled immediately, he said.
Roche Taiwan said in a statement released last night that it "feels confused and regret" toward the IPO's compulsory license decision.
The company said it is concerned about the quality of vaccine developed by Taiwan's Vaccine Center under the National Health Research Institute.
But to ease public concern, "the company will try its best ... to increase imports of the original Tamiflu from elsewhere around the world to meet Taiwan's demand, and is confident that the company can import enough of the drug to reach a safe level as requested by both the DOH and IPO," Roche said in the statement.
Also see story:
RETHINK? The defense ministry and Navy Command Headquarters could take over the indigenous submarine project and change its production timeline, a source said Admiral Huang Shu-kuang’s (黃曙光) resignation as head of the Indigenous Submarine Program and as a member of the National Security Council could affect the production of submarines, a source said yesterday. Huang in a statement last night said he had decided to resign due to national security concerns while expressing the hope that it would put a stop to political wrangling that only undermines the advancement of the nation’s defense capabilities. Taiwan People’s Party Legislator Vivian Huang (黃珊珊) yesterday said that the admiral, her older brother, felt it was time for him to step down and that he had completed what he
Taiwan has experienced its most significant improvement in the QS World University Rankings by Subject, data provided on Sunday by international higher education analyst Quacquarelli Symonds (QS) showed. Compared with last year’s edition of the rankings, which measure academic excellence and influence, Taiwanese universities made great improvements in the H Index metric, which evaluates research productivity and its impact, with a notable 30 percent increase overall, QS said. Taiwanese universities also made notable progress in the Citations per Paper metric, which measures the impact of research, achieving a 13 percent increase. Taiwanese universities gained 10 percent in Academic Reputation, but declined 18 percent
UNDER DISCUSSION: The combatant command would integrate fast attack boat and anti-ship missile groups to defend waters closest to the coastline, a source said The military could establish a new combatant command as early as 2026, which would be tasked with defending Taiwan’s territorial waters 24 nautical miles (44.4km) from the nation’s coastline, a source familiar with the matter said yesterday. The new command, which would fall under the Naval Command Headquarters, would be led by a vice admiral and integrate existing fast attack boat and anti-ship missile groups, along with the Naval Maritime Surveillance and Reconnaissance Command, said the source, who asked to remain anonymous. It could be launched by 2026, but details are being discussed and no final timetable has been announced, the source
CHINA REACTS: The patrol and reconnaissance plane ‘transited the Taiwan Strait in international airspace,’ the 7th Fleet said, while Taipei said it saw nothing unusual The US 7th Fleet yesterday said that a US Navy P-8A Poseidon flew through the Taiwan Strait, a day after US and Chinese defense heads held their first talks since November 2022 in an effort to reduce regional tensions. The patrol and reconnaissance plane “transited the Taiwan Strait in international airspace,” the 7th Fleet said in a news release. “By operating within the Taiwan Strait in accordance with international law, the United States upholds the navigational rights and freedoms of all nations.” In a separate statement, the Ministry of National Defense said that it monitored nearby waters and airspace as the aircraft